Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 14.63%
As of Thursday, January 08, Jasper Therapeutics, Inc.’s JSPR share price has dipped by 14.63%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 24.39%
As of Thursday, January 08, Jasper Therapeutics, Inc.’s JSPR share price has dipped by 24.39%, which has investors questioning if this is right time to buy.Omar Beirat
Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 6.32%
As of Wednesday, January 07, Jasper Therapeutics, Inc.’s JSPR share price has surged by 6.32%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.43%
As of Monday, December 01, Jasper Therapeutics, Inc.’s JSPR share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 10.38%
As of Friday, November 07, Jasper Therapeutics, Inc.’s JSPR share price has dipped by 10.38%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | JSPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $17.6 | $252.6 | 9% |
|
| Shares Out (Mil) | 28.7 | 52.3 | 36% |
|
| Institutional Ownership | 93.4% | 92.1% | 63% |
|
| Float (Mil) | 23.3 | 40.2 | 31% |
|
| Beta | 3.01 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 892 | 455 | 68% |
|
| Price Change (52-week) |
(78.7%) | 52.9% | 7% |
|
| Growth | JSPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (19.0%) | (9.9%) | 21% |
|
| EPS (5yr) | 53.6% | 16.0% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 43.9% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.550) | ($2.410) | ($2.560) | |
| Month Ago EPS | ($0.550) | ($2.410) | ($2.560) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.550) | ($2.440) | ($1.670) | |
| Year/Year Chg | 1,242% | (39.1%) | (34.0%) | |
| Financials | JSPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($56) | ($43) | 15% |
|
| EPS (TTM) | ($2.468) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $180 | 3% |
|
| Valuation | JSPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.25 | 2.56 | 79% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | JSPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (141.5%) | (49.8%) | 3% |
|
| ROE | (244.2%) | (55.5%) | 3% |
|
| Liabilities to Assets | 84.0% | 30.3% | 78% |
|
| F-Score | 1 | 3 | 1% |
|
Jasper Therapeutics, Inc. did not pass any screens on 7/31/2026.
